T2 Biosystems Inc. hired the Cambridge, U.K.-based consulting firm Sagentia to shepherd the development of its portable diagnostics system.
The Cambridge, Mass.-based start-up is developing nano- and miniaturized magnetic resonance-based technology for use in a bench-top instrument for small molecule diagnostics, according to Sagentia.
In May, T2 raised $15 million in a Series C funding round to support the development of the technology.
The use of MR technology is faster, more reliable and may be less expensive for both molecular and immunodiagnostics applications because it requires less processing than optical-based diagnostic tool require, according to Sagentia.
T2’s technology "will offer improved speed, accuracy and efficiency as well as portability to a broader range of settings including doctors’ offices, homes and hospitals," Sagentia CEO Brent Hudson said in prepared remarks. "This project also clearly reflects the wider trend we are seeing towards growth in the point of care diagnostics market," he said.
In November, Sagentia opened up a location in Cambridge, Mass., less than one mile from T2’s headquarters.
Specific terms of the deal were not released.